Allopurinol

Generic Name: Allopurinol

Brand Names: Aloprim, Zyloprim

Drug Type: Small Molecule

Chemical Formula: C_₅H_₄N_₄O

CAS Number: 315-30-0

Unique Ingredient Identifier: 63CZ7GJN5I

Background: Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals .

Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout . It was initially approved by the FDA in 1966 and is now formulated by several manufacturers .

Indication: Allopurinol is indicated in :

1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).

2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present.

3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Associated Conditions: Hyperuricemia, Primary Gout, Recurrent calcium oxalate calculi, Secondary gout, Calcium oxalate calculi Renal Calculi

Clinical Trials

The Effect of Antioxidants on Skin Blood Flow During Local Heating

Phase 1

Completed

Conditions: Cardiovascular Diseases
Vasodilation
Cardiovascular Risk Factor

Interventions: Drug: Apocynin
Drug: Allopurinol
Other: Control (Lactated Ringer's)
Drug: Tempol

First Posted Date: 2018-09-21

Last Posted Date: 2018-09-21

Lead Sponsor: The University of Texas at Arlington

Target Recruit Count: 44

Registration Number: NCT03680638

Locations: 🇺🇸
Engineering Research Building, Arlington, Texas, United States

Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid

Phase 2

Completed

Conditions: Hyperuricemia
Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Other: Low-fructose diet, isocaloric
Other: Low-fructose, hypocaloric
Drug: Allopurinol

First Posted Date: 2018-08-28

Last Posted Date: 2023-07-03

Lead Sponsor: University of Missouri-Columbia

Target Recruit Count: 34

Registration Number: NCT03648996

Locations: 🇺🇸
University of Missouri, Columbia, Missouri, United States

The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients

Not Applicable

Conditions: Gout

Interventions: Drug: Allopurinol

First Posted Date: 2018-07-26

Last Posted Date: 2018-07-26

Lead Sponsor: Hillel Yaffe Medical Center

Target Recruit Count: 700

Registration Number: NCT03601260

Locations: 🇮🇱
Hillel Yaffe Medical Center, Hadera, Israel

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Allopurinol
Drug: Carmustine
Drug: Melphalan
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2018-06-27

Last Posted Date: 2022-06-22

Lead Sponsor: Swedish Medical Center

Target Recruit Count: 100

Registration Number: NCT03570983

Locations: 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States

Comparative Clinical Efficacy and Safety of Coded Polyherbal Medicine for the Management of Arthritis

Phase 1

Conditions: Treatment of Arthritis

Interventions: Drug: Allopurinol

First Posted Date: 2018-04-24

Last Posted Date: 2018-04-24

Lead Sponsor: Shifa Ul Mulk Memorial Hospital

Target Recruit Count: 200

Registration Number: NCT03506919

Locations: 🇵🇰
clinical trial was conducted in Bahawalpur, and Rawalpindi, Bahawalpur, Punjab, Pakistan

Allopurinol and Endothelial Function in Diabetic CAD Patients

Not Applicable

Conditions: Coronary Artery Disease
Diabetes Mellitus

Interventions: Drug: Allopurinol

First Posted Date: 2017-12-28

Last Posted Date: 2017-12-28

Lead Sponsor: University Tunis El Manar

Target Recruit Count: 58

Registration Number: NCT03385135

Locations: 🇹🇳
Cardiology Department, Abderrahmen Mami Hospital, Ariana, Tunisia

Lowering Uric Acid in Live Kidney Donors

Phase 2

Completed

Conditions: Renal Transplant Donor of Right Kidney
Renal Transplant Donor of Left Kidney

Interventions: Drug: Placebo Oral Tablet
Drug: Allopurinol 300 mg

First Posted Date: 2017-11-27

Last Posted Date: 2021-02-24

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 71

Registration Number: NCT03353298

Locations: 🇳🇴
Oslo University Hospital, Oslo, Norway

PERL Continuous Glucose Monitoring (CGM) Study

Completed

Conditions: Diabetic Nephropathies

Interventions: Other: Mean blood glucose
Other: Blood glucose CV
Other: % time 70-180 mg/dL
Other: % time below 54 mg/dL
Other: % time above 180 mg/dL
Other: % time above 250 mg/dL
Other: MAGE (Mean amplitude of glucose excursions)
Other: LBGI (Low Blood Glucose Index)
Other: HBGI (High Blood Glucose Index)
Drug: Placebo
Drug: Allopurinol

First Posted Date: 2017-11-07

Last Posted Date: 2022-03-29

Lead Sponsor: Joslin Diabetes Center

Target Recruit Count: 175

Registration Number: NCT03334318

Locations: 🇺🇸
ICAHN School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States
🇨🇦
Unversity of Calgary, Calgary, Alberta, Canada

and more 16 locations